Medication info
Esplitin M Tablets 50/850 mg

Esplitin M Tablets 50/850 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride with Colloidal Anhydrous Silica›858.5mg / 1 tablet
Manufacturer / importer
Widus Pharmaceutical Co., Ltd.
Appearance
Pink oval film-coated tablets
Packaging
30 tablets/box [10 tablets/PTP X 3]
Approval status
Active

MFDS item code 202200333 · Approved 2022.01.20 · Insurance code 660703800

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with meals. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this drug should be based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients who have not previously received pharmacological treatment for diabetes and whose glycemic control is inadequate with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this drug is one 50/500 mg tablet twice daily. The dose may be increased to one 50/1000 mg tablet twice daily. Patients with renal impairment receiving a reduced dose of sitagliptin should not be switched to this drug (see section 2, Contraindications, in Precautions for Use). 2. Patients receiving metformin: - For patients whose glycemic control is inadequate with metformin monotherapy, the recommended initial dose of this drug is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. 3. Patients whose glycemic control is inadequate with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When this drug is administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see section 5, General Precautions, in Precautions for Use). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral glucose-lowering agent to this drug. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this drug, as the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see section 2, Contraindications, in Precautions for Use).

Ingredients

Manufacturer
Widus Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

  • Type 2 diabetes
  • difficulty in blood sugar control
View approved original text

This medication is used to assist in blood sugar control for patients with type 2 diabetes. It is administered as an adjunct to diet and exercise for patients who have difficulty controlling their blood sugar. It may be used alone if the patient has no prior experience with diabetes medication, and is an alternative when metformin or sitagliptin alone is ineffective. Additionally, this medication is added when there is insufficient blood sugar control with metformin combined with sulfonylurea, or metformin combined with thiazolidinedione. In cases where insulin combined with metformin is also insufficient, this medication is added to improve blood sugar control. Therefore, this medication effectively improves blood sugar control in type 2 diabetes in conjunction with various treatment methods.

How to take

Adult dose

For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with meals. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this drug should be based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients who have not previously received pharmacological treatment for diabetes and whose glycemic control is inadequate with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this drug is one 50/500 mg tablet twice daily. The dose may be increased to one 50/1000 mg tablet twice daily. Patients with renal impairment receiving a reduced dose of sitagliptin should not be switched to this drug (see section 2, Contraindications, in Precautions for Use). 2. Patients receiving metformin: - For patients whose glycemic control is inadequate with metformin monotherapy, the recommended initial dose of this drug is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. 3. Patients whose glycemic control is inadequate with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When this drug is administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see section 5, General Precautions, in Precautions for Use). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral glucose-lowering agent to this drug. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this drug, as the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see section 2, Contraindications, in Precautions for Use).

Precautions

This medication is used for the treatment of diabetes and helps regulate blood sugar levels. Allergic reactions may occur within the first 3 months of administration, so if symptoms such as skin rash, respiratory distress, or swelling of the face or neck appear, discontinue the medication immediately and consult a doctor. There is a risk of inflammation in the pancreas, known as acute pancreatitis, so any symptoms such as abdominal pain, nausea, or vomiting should be reported to healthcare professionals immediately. It should not be administered to patients with severely impaired kidney function, acute infections, heart failure, or dehydration, and should be discontinued for a period before and after surgery. This medication should not be used in pregnant or nursing women. It may cause hypoglycemia, so it is important to eat regularly and be cautious during vigorous exercise. Additionally, elderly patients or those with liver or kidney problems should have regular function tests, and it is advisable to check for decreased vitamin B12 levels through blood tests during medication use. Alcohol consumption can increase the risk of serious side effects such as lactic acidosis, so it should be avoided. Do not take other medications or dietary supplements without consulting a doctor while on this medication, especially since the risk of hypoglycemia may increase when used with other blood sugar-lowering agents. If an overdose occurs, visit a medical institution immediately for appropriate treatment, as blood dialysis may be required. Lastly, regular blood sugar tests, kidney function tests, and symptom monitoring are important while taking this medication, so it should be taken consistently as prescribed and any abnormal symptoms should be reported to a specialist immediately.

Side effects

Anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory infection, headache, nausea, vomiting, abdominal pain, nasopharyngitis, constipation, severe pain in joints accompanied by disability, vesicular pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, dermatitis, anorexia, weight loss, neutrophilia, elevated liver enzymes, acute renal failure, decreased appetite, itching, dizziness, dyspnea, unstable angina, dizziness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air ingress, at room temperature between 1 and 30 degrees Celsius. Storing it this way helps maintain the drug's efficacy and prevents degradation.

Appearance and packaging

Appearance

Pink oval film-coated tablets

Package unit

30 tablets/box [10 tablets/PTP X 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.